B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
First Claim
Patent Images
1. A molecule that binds to B-cell Specific Antigen (BLSA) (SEQ ID NO 2).
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides vaccines, antibodies, and diagnostic tools for the diagnosis and/or treatment of B-cell mediated diseases, particularly B-cell lymphomas.
46 Citations
46 Claims
- 1. A molecule that binds to B-cell Specific Antigen (BLSA) (SEQ ID NO 2).
-
13. A vaccine for the treatment of a B-cell lymphoma comprising a polypeptide comprising an amino sequence selected from the group consisting of:
- SEQ ID NO;
2;
a variant of SEQ ID NO;
2; and
a fragment of SEQ ID NO;
2, wherein the peptide contains at least one epitope. - View Dependent Claims (15, 16, 17, 18, 21)
- SEQ ID NO;
-
14. A vaccine for the treatment of B-cell lymphoma comprising a polypeptide encoded by an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
- SEQ ID NO;
1;
a variant of SEQ ID NO;
1; and
a fragment of SEQ ID NO;
1, wherein the peptide contains at least one epitope.
- SEQ ID NO;
- 19. A DNA construct comprising a nucleic acid sequence which expresses BLSA or an immunogenic fragment thereof, operably linked to a promoter.
-
22. A method for inducing an immune response in a mammal against BLSA comprising administering a composition comprising a DNA molecule that encodes BLSA, said DNA molecule operatively linked to regulatory sequences which control the expression of said DNA molecule, wherein BLSA is expressed in said cells and an immune response is generated against BLSA.
-
23. A BLSA peptide comprising at least one epitope that induces a cytotoxic T-Lymphocyte (CTL) response.
-
24. A method of inducing an immune response in a mammal against BLSA comprising administering a cytotoxic T-Lymphocyte (CTL)-inducing peptide.
- 25. A method of inducing an immune response in a mammal against BLSA comprising administering a vector that expresses a cytotoxic T-Lymphocyte (CTL)-inducing peptide of BLSA.
-
26. A host cell comprising a vector that expresses a cytotoxic T-Lymphocyte (CTL)-inducing peptide of BLSA.
-
27. A method for inhibiting the expression of BLSA by administering a composition that decreases the rate of translation of BLSA in a B-cell lymphoma cell, comprising exposing the cell to an antisense nucleic acid or antisense nucleic acid mimic that hybridizes to said RNA species or to DNA encoding said RNA species.
-
28. A method for screening for an agent with the ability to modulate expression of BLSA comprising the steps of:
-
(a) contacting a cell comprising the gene encoding BLSA with a candidate agent under conditions sufficient to permit modulation of the level of mRNA transcribed from the BLSA gene;
(b) isolating mRNA;
(c) comparing the amount of detected mRNA with an amount detected in the absence of candidate agent, and therefrom determining the ability of the candidate agent to modulate expression of BLSA. - View Dependent Claims (30)
-
-
29. A method for screening for an agent with the ability to bind BLSA comprising the steps of:
-
(a) contacting BLSA with a candidate agent under conditions sufficient to permit binding;
(b) detecting the presence of a BLSA/agent complex.
-
- 31. A method for blocking or modulating the expression of a cellular BLSA by interfering with the transcription or translation of a DNA or RNA polynucleotide encoding the BLSA comprising exposing a cell capable of expressing a BLSA to a molecule that interferes with the transcription or translation of a DNA or RNA polynucleotide encoding the BLSA.
-
34. A method for diagnosing the predisposition of a patient to develop a B-cell mediated disease caused by the unregulated expression of BLSA, comprising:
-
collecting a cell, tissue, or body fluid sample from a patient;
analyzing the tissue or body fluid for the presence of BLSA; and
predicting the predisposition of the patient to B-cell mediated diseases based upon the level of expression of BLSA in the tissue or body fluid.
-
-
35. A method for diagnosing the predisposition of a patient to develop a B-cell mediated disease caused by the unregulated expression of BLSA, comprising:
-
collecting a cell, tissue, or body fluid sample known to contain a defined level of BLSA from a patient;
analyzing the tissue or body fluid for the amount of BLSA in the tissue; and
predicting the predisposition of the patient to certain immune diseases based upon the change in the amount of BLSA in the tissue or body fluid compared to a defined or tested level extablished for normal cell, tissue, or bodly fluids.
-
-
35-1. A method for preventing or treating BLSA protein mediated diseases in a mammal comprising administering a disease preventing or treating amount of a BLSA agonist or antagonist to the mammal.
-
37. A method for producing an antibody that binds to BLSA, comprising a method selected from the group consisting of:
-
using isolated BLSA or antigenic fragments thereof as an antigen;
using host cells that express recombinant BLSA as an antigen; and
using DNA expression vectors containing the BLSA gene to express BLSA as an antigen for producing antibodies. - View Dependent Claims (38, 39, 40)
-
-
41. A method for isolating and purifying BLSA from recombinant cell culture, contaminants, and native environments, comprising:
-
exposing a composition containing BLSA and contaminants to an antibody capable of binding to BLSA;
allowing the BLSA to bind to the antibody;
separating the antibody-BLSA complexes from the contaminants; and
recovering the BLSA from the complexes.
-
-
43. A transgenic knockout animal whose genome comprises a heterozygous or homozygous disruption in its endogenous BLSA gene that suppresses or prevents the expression of biologically functional BLSA proteins.
-
44. A method for imaging lesions characteristic of certain lymphomas, comprising the steps of:
obtaining monoclonal antibody specific to BLSA;
labeling said antibody;
contacting said labeled antibody with a biological sample obtained from a mammal; and
imaging said label.
-
45. A method for detecting the level of BLSA in a cell comprising performing quantitative PCR.
-
46. A method for detecting BLSA in a cell comprising performing immunofluorescence staining.
Specification